Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-01-10
2010-11-02
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S237200, C514S252180, C514S278000, C514S312000, C514S314000, C514S318000, C514S333000, C514S338000, C544S124000, C544S364000, C546S015000, C546S152000, C546S153000, C546S187000, C546S256000, C546S273100
Reexamination Certificate
active
07825115
ABSTRACT:
The disclosure relates to a cyclic urea compound of formula I:as defined herein, to the process for its preparation, pharmaceutical composition comprising it and its pharmaceutical use as an inhibitor on a protein kinase. Thus, the compound of formula I is useful for preventing or treating a physiological disorder capable of being modulated by inhibiting the activity of a protein kinase, such as a solid tumor.
REFERENCES:
patent: 4097578 (1978-06-01), Perronnet et al.
patent: 5276049 (1994-01-01), Himmelsbach et al.
patent: 5554594 (1996-09-01), Zoller et al.
patent: 6004963 (1999-12-01), Zimmer et al.
patent: 6022875 (2000-02-01), Zimmer et al.
patent: 6759415 (2004-07-01), Poitout et al.
patent: 2007/0259891 (2007-11-01), Strobel et al.
patent: 2008/0004300 (2008-01-01), Strobel et al.
patent: 2008/0021029 (2008-01-01), Strobel et al.
patent: 0 503 548 (1992-09-01), None
patent: 0584694 (1994-03-01), None
patent: 0770613 (1997-05-01), None
patent: WO 97/38984 (1997-10-01), None
patent: WO 98/39303 (1998-09-01), None
patent: WO 01/09090 (2001-02-01), None
patent: WO 01/56996 (2001-08-01), None
patent: WO 01/92253 (2001-12-01), None
Dyer et al., CAPLUS Abstract 71:39529, 1969.
Cressey et al, Alteration of Protein Expression Pattern of Vascular Endothelial Growth Factor (VEGF) From Soluble to Cell-Associated Isoform During Tumourigenesis, Medline Abstract (BMC Cancer, vol. 5, p. 128) Oct. 2005.
Damasio, Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, 20th Edition, vol. 2, pp. 1992-1996, 1996.
Fabbro et al, Protein Kinases as Targets for Anticancer Agents: From Inhibitors to useful Drugs, Pharmacology & Therapeutics, 93, pp. 79-98, 2002.
Layzer, Degenerative Diseases of the Nervous System, Cecil Textbook of Medicine, 20th Edition, vol. 2, pp. 2050-2057, 1996.
Simone, Oncology: Introduction, Cecil Textbook of Medicine, 20th Edition, vol. 1, pp. 1004-1010, 1996.
Traxler, Protein Tyrosine kinase Inhibitors in Cancer Treatment, Exp. Opin. Ther. Patents, 7(6), pp. 571-588, 1997.
Yano et al, Treatment for Malignant Pleural Effusion of Human Lung Adenocarcinoma by Inhibition of Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Phosphorylation, Medline Abstract (Clinical Cancer Research: An Official Journal of The American Assoc. for Cancer Research, vol. 6, Issue 3, pp. 957-965) Mar. 2000.
U.S. Appl. No. 12/173,191, filed Jul. 15, 2008, Halley et al.
U.S. Appl. No. 12/173,380, filed Jul. 15, 2008, Halley et al.
Al-Obeidi Fahad
Benard Didier
Bond Daniel
Bouchard Herve
El-Ahmad Youssef
Aventis Pharma S.A.
Bender Kelly L.
Rao Deepak
LandOfFree
Cyclic urea compounds, preparation thereof and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclic urea compounds, preparation thereof and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic urea compounds, preparation thereof and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4178398